Last updated: February 27, 2026
What is the Approved Drug and Its Therapeutic Context?
NDC 70748-0332 corresponds to Rimegepant Oral Tablets (sold under the brand name Nurtec ODT). Approved by the FDA in February 2020, it is indicated for the acute treatment of migraine with or without aura in adults and for the preventive treatment of episodic migraine. This drug belongs to the calcitonin gene-related peptide (CGRP) receptor antagonist class, a key component in migraine management.
Market Size and Growth Drivers
Therapeutic Market Scope
- Global migraine market valued at approximately $4.9 billion in 2022.
- Expected compound annual growth rate (CAGR): 4.3% (2023-2030), projected to reach $7.2 billion by 2030.
- Growth driven by increasing migraine prevalence, expanding indications, and novel CGRP therapies.
Patient Population
- Estimated 39 million Americans suffer from migraine (American Migraine Foundation).
- About 40% of sufferers seek acute treatment; roughly 20% use preventive therapies.
- Rimegepant targets a subset of these patients, primarily those seeking oral options instead of injections.
Competitive Landscape
- Key competitors include:
- Erenumab (Aimovig): injectable CGRP monoclonal antibody.
- Ubrogepant (Ubrelvy): oral CGRP antagonist, similar to rimegepant.
- Sumatriptan: older selective serotonin receptor agonist.
- Ubrogepant launched in 2019; its sales growth impacts market share for rimegepant.
Market Penetration
- As of 2022, Nurtec ODT captured an estimated 35% of the acute migraine treatment market among oral drugs.
- Prescriptions are growing, but market share varies regionally, with higher uptake in the US.
Pricing Analysis
Current Pricing
- Average wholesale price (AWP): approximately $37 for a 10-tablet package of Nurtec ODT (per 75 mg tablet) [2].
- Average retail price: roughly $40–$45 per pack.
- Insurance and pharmacy benefit managers often negotiate discounts, leading to lower net prices.
Discounting and Reimbursement
- Typical discounts: 20-30% off AWP for commercial payers.
- Medicare Part D coverage favors lower co-pays; average out-of-pocket costs range $10–$30.
- Pharmacoeconomic evaluations support favorable reimbursement profiles due to high efficacy and patient preference.
Price Trends and Projections
| Year |
Projected Wholesale Price per Pack |
Key Factors |
| 2023 |
$37–$40 |
Stable, with ongoing negotiations |
| 2025 |
$36–$39 |
Slight decline expected with increased competition |
| 2030 |
$35–$38 |
Market maturity and biosimilar entry possible |
Factors Influencing Price
- Competitive pressure from generic Ubrogepant or biosimilar CGRP antagonists.
- Market penetration: increased use in prevention therapy may shift focus depending on payer reimbursement.
- Regulatory developments: approval of new indications or formulations.
- Manufacturing costs: reduction through economies of scale.
Regulatory and Market Access Impact
- Expanding indications could drive volume, stabilizing or slightly reducing prices.
- Payer negotiations may favor discounts or value-based agreements.
- Entry of generics or biosimilars could lower prices by 20–30% within 3-5 years of patent expiration.
Key Takeaways
- The U.S. migraine treatment market is expanding at a CAGR of 4.3%, driven by increased prevalence and new therapies.
- Nurtec ODT holds approximately 35% market share among oral acute treatments, with steady growth.
- Current average prices hover around $37–$45 per pack; discounts and negotiations reduce net prices.
- Price projections indicate stability through 2025, with potential declines aligned with increased competition and patent cycles.
- Market dynamics are heavily influenced by regulatory changes, payer strategies, and competitor actions.
FAQs
1. How does the price of Nurtec compare to other migraine treatments?
Nurtec's price per pack aligns with other oral CGRP antagonists like Ubrelvy, which ranges from $35–$45. Injectable CGRP antibodies are significantly more expensive, often exceeding $600 per month.
2. What factors could lead to a price decline for Nurtec?
Introduction of generic or biosimilar alternatives, increased market competition, and payer pressure may drive prices down by 20–30% over the next 3–5 years.
3. How do insurance policies impact out-of-pocket costs for patients?
Rebates, negotiated discounts, and formulary placement influence copay amounts. Typically, patients pay between $10–$30 for covered prescriptions.
4. What is the potential market for preventive use of Nurtec?
Market expansion into preventive treatment could increase patient volume by an estimated 10–15%, but reimbursement policies must adapt accordingly.
5. What upcoming regulatory or market developments could affect prices?
Regulatory approvals for additional indications, new formulations, or biosimilar entrants could alter pricing dynamics within the forecast period.
References
- American Migraine Foundation. (2022). Migraine statistics. Retrieved from https://americanmigrainefoundation.org
- IQVIA. (2022). National Prescription Audit, Q4 2022.
- EvaluatePharma. (2023). World Preview 2023: Healthcare Market Forecasts.
- U.S. Food and Drug Administration. (2020). FDA approves Nurtec ODT for migraine.
- Drugs.com. (2023). Nurtec ODT (rimegepant) price and discounts.
